基于记忆性干性T细胞和中心记忆性T细胞的细胞免疫治疗在血液肿瘤治疗中的价值

Therapeutic value of immune cell therapy based on T memory stem cells and central memory T cells for hematological malignancies

近年来，以抗原嵌合受体T细胞（CAR-T）为代表的细胞免疫治疗在血液肿瘤治疗中取得重大突破。记忆性干性T细胞（TSCM）和中心记忆性T细胞（TCM）是T细胞免疫治疗强有力的载体，如何在体内及体外调控该类细胞的分化、如何利用其构建强效的治疗系统而避免潜在的毒副作用受到研究者们的关注。文章主要总结了第58届美国血液学会（ASH）年会关于TSCM和TCM在血液肿瘤治疗中的价值和相关研究进展。

In recent years, cellular immune therapy represented by antigen-chimeric receptor T cells （CAR-T） has made a great breakthrough in the treatment of hematological malignancies. T memory stem cells （TSCM） and central memory T cells （TCM） can be used as most powerful carrier for T cell immunotherapy, however, how to regulate their differentiation in vitro and in vivo as well as how to construct a strong treatment system while without potential side effect become quite interesting. This article summarized the studies from the 58th America Society of Hematology Annual Meeting regarding to values and associated research progress about TSCM and TCM in hematological malignancies.